

Stephen M Montgomery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6454160/publications.pdf>

Version: 2024-02-01

15
papers

98
citations

1683354

5
h-index

1372195

10
g-index

15
all docs

15
docs citations

15
times ranked

144
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. <i>Journal of Medical Economics</i> , 2015, 18, 874-885. | 1.0 | 23 |
| 2 | Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Value in Health</i> , 2015, 18, 925-938. | 0.1 | 19 |
| 3 | A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. <i>Journal of Medical Economics</i> , 2017, 20, 474-482. | 1.0 | 17 |
| 4 | Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. <i>Journal of Medical Economics</i> , 2017, 20, 962-973. | 1.0 | 11 |
| 5 | The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 347-350. | 0.7 | 9 |
| 6 | When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis. <i>Journal of Medical Economics</i> , 2018, 21, 983-992. | 1.0 | 6 |
| 7 | A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence. <i>Clinical Drug Investigation</i> , 2016, 36, 945-956. | 1.1 | 5 |
| 8 | Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. <i>Health Science Reports</i> , 2022, 5, e474. | 0.6 | 3 |
| 9 | Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. <i>Journal of Medical Economics</i> , 2022, 25, 669-678. | 1.0 | 3 |
| 10 | Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 545-558. | 1.0 | 2 |
| 11 | Economic orphans? the prevalence of child-specific utilities in nice appraisals for paediatric indications. <i>Value in Health</i> , 2014, 17, A326-A327. | 0.1 | 0 |
| 12 | Systematic Review and Critique of Health Economic Models on Relapsing-Remitting Multiple Sclerosis in the UK. <i>Value in Health</i> , 2014, 17, A548. | 0.1 | 0 |
| 13 | An Undeveloped Picture: The Availability Of Utility Valuations In Latin America – How Will They Affect Qalys?. <i>Value in Health</i> , 2015, 18, A811. | 0.1 | 0 |
| 14 | Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?. <i>Value in Health</i> , 2015, 18, A487. | 0.1 | 0 |
| 15 | RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy, and Spain. <i>Journal of Medical Economics</i> , 2019, 22, 379-380. | 1.0 | 0 |